Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

121. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett`s esophagus (Full text)

Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett`s esophagus Limited evidence suggests that proton pump inhibitors (PPI), nonsteroidal anti-inflammatory drugs (NSAID)/aspirin, and statins may be associated with a low risk of esophageal neoplasia. However, the possible effect these medications may have on the risk of esophageal adenocarcinoma (EAC) in patients with existing Barrett's esophagus (BE) is unclear.We conducted

2010 EvidenceUpdates PubMed

122. Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention (PubMed)

Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention Recent studies have suggested that proton pump inhibitors (PPIs) might reduce the inhibitory effect of clopidogrel on platelet aggregation, possibly through inhibition of the hepatic cytochrome P450 2C19 (CYP2C19) isoenzyme. The prevalence of CYP2C19 loss-of-function alleles is much greater among East Asians than among other

2010 EvidenceUpdates

123. Proton pump inhibitors and risk for recurrent Clostridium difficile infection (Full text)

Proton pump inhibitors and risk for recurrent Clostridium difficile infection Proton pump inhibitors (PPIs) are widely used gastric acid suppressants, but they are often prescribed without clear indications and may increase risk of Clostridium difficile infection (CDI). We sought to determine the association between PPI use and the risk of recurrent CDI.Retrospective, cohort study using administrative databases of the New England Veterans Healthcare System from October 1, 2003, through (...) determined that the adjusted HR of recurrent CDI was greater in those exposed to PPIs during treatment (1.42; 95% confidence interval [CI], 1.11-1.82). Risks among exposed patients were highest among those older than 80 years (HR, 1.86; 95% CI, 1.15-3.01) and those receiving antibiotics not targeted to C difficile during follow-up (HR, 1.71; 95% CI, 1.11-2.64). [corrected]Proton pump inhibitor use during incident CDI treatment was associated with a 42% increased risk of recurrence. Our findings warrant

2010 EvidenceUpdates PubMed

124. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women`s Health Initiative (Full text)

Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women`s Health Initiative Proton pump inhibitor (PPI) medications have been inconsistently shown to be associated with osteoporotic fractures. We examined the association of PPI use with bone outcomes (fracture, bone mineral density [BMD]).This prospective analysis included 161 806 postmenopausal women 50 to 79 years old, without history of hip fracture, enrolled in the Women's

2010 EvidenceUpdates PubMed

125. WITHDRAWN: Proton pump inhibitor treatment for acute peptic ulcer bleeding. (PubMed)

WITHDRAWN: Proton pump inhibitor treatment for acute peptic ulcer bleeding. Randomised controlled trials (RCTs) evaluating the clinical effect of proton pump inhibitors (PPIs) in peptic ulcer (PU) bleeding yield conflicting results.To evaluate the efficacy of PPIs in acute bleeding from PU using evidence from RCTs.We searched CENTRAL, The Cochrane Library (Issue 4, 2004), MEDLINE (1966 to November 2004), EMBASE (1980 to November 2004), proceedings of major meetings to November 2004

2010 Cochrane

126. Impact of proton pump inhibitors on benign anastomotic stricture formations after esophagectomy and gastric tube reconstruction: results from a randomized clinical trial (PubMed)

Impact of proton pump inhibitors on benign anastomotic stricture formations after esophagectomy and gastric tube reconstruction: results from a randomized clinical trial The primary aim of this study was to evaluate if the use of proton pump inhibitors (PPIs) reduced the prevalence of benign anastomotic strictures after uncomplicated esophagectomies with gastric tube reconstruction and circular stapled anastomoses.Benign anastomotic strictures are associated with anastomotic leaks or conduit

2010 EvidenceUpdates

127. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID

ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID nature publishing group the red section 2533 Writing Committee Members Neena S. Abraham, MD, FACG, Chair*; Mark A. Hlatky, MD, FACC, FAHA, Vice Chair† Elliott M. Antman, MD, FACC, FAHA‡; Deepak L. Bhatt, MD, MPH, FACC, FAHA† David J. Bjorkman (...) KW , Quigley EM, Scheiman J, Sper - ling LS, Tomaselli GF (. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2010;105:2533–2549; doi:10.1038/ajg.2010.445. This article has been copublished in the Journal of the American College of Cardiology and Circulation. Copies

2010 American College of Gastroenterology

128. Clopidogrel and proton pump inhibitors: interaction?updated advice

Clopidogrel and proton pump inhibitors: interaction?updated advice Clopidogrel and proton pump inhibitors: interaction—updated advice - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Clopidogrel and proton pump inhibitors: interaction—updated advice In light of the most recent evidence, the previous advice on the concomitant use of clopidogrel with proton pump inhibitors has now been modified. Use of either omeprazole or esomeprazole with clopidogrel should be discouraged (...) . Proton pump inhibitors (PPIs) are indicated for the treatment of oesophageal reflux disease, dyspepsia, or gastric ulcers, and are frequently co-prescribed with clopidogrel. Previous advice regarding an interaction In May 2009, the EU Committee for Medicinal products for Human Use (CHMP) concluded that concomitant use of any PPIs with clopidogrel should be avoided unless considered essential. See . The product information for clopidogrel has been recently updated on the basis of pharmacokinetic

2010 MHRA Drug Safety Update

129. High-dose vs low-dose proton pump inhibitors for upper gastrointestinal bleeding: a meta-analysis (Full text)

High-dose vs low-dose proton pump inhibitors for upper gastrointestinal bleeding: a meta-analysis High-dose vs low-dose proton pump inhibitors for upper gastrointestinal bleeding: a meta-analysis High-dose vs low-dose proton pump inhibitors for upper gastrointestinal bleeding: a meta-analysis Wu LC, Cao YF, Huang JH, Liao C, Gao F CRD summary This generally well-conducted review concluded that the low-dose intravenous proton-pump inhibitors achieved the same efficacy as high-dose proton-pump (...) inhibitors following endoscopic haemostasis in patients with upper gastrointestinal bleeding. The authors' conclusions reflect the evidence presented, but should be interpreted with a degree of caution given the limited quality and size of most of the included trials. Authors' objectives To assess the efficacy of high-dose versus low-dose proton-pump inhibitors for the treatment of upper gastrointestinal bleeding. Searching The following databases were searched up to September 2009 without language

2010 DARE. PubMed

130. The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis

The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients (...) : a meta-analysis Lin PC, Chang CH, Hsu PI, Tseng PL, Huang YB CRD summary This review found there were no differences in outcomes between treatment with proton pump inhibitors and histamine-2 receptor antagonists for critical care patients in intensive care units. The authors' cautious conclusions reflect the evidence presented, but the poor quality of the included trials and the potential for publication and language biases should be considered when interpreting the results. Authors' objectives

2010 DARE.

131. Proton Pump Inhibitors for Acute Upper GI Bleeding

Proton Pump Inhibitors for Acute Upper GI Bleeding Proton Pump Inhibitors for Acute Upper GI Bleeding – TheNNTTheNNT Proton Pump Inhibitors (PPIs) Given for Acute Upper Gastrointestinal Bleeding Given Prior to Endoscopic Diagnosis No benefit found In Summary, for those who took the PPI: Benefits in NNT 100% saw no benefit 0% were helped by being saved from death, needing surgery, preventing repeat bleeding None were helped (life saved, preventing surgery, prevent repeat bleeding) Harms in NNT (...) gastrointestinal bleeding is a potentially life threatening condition that can demand aggressive intervention from the emergency physicians. Although bleeding can originate in any area above the ligament of Treitz, the majority of bleeding is from a peptic ulcer , . Proton pump inhibitors (PPIs) work by reducing gastric acid secretion, neutralizing gastric pH, increasing clot formation and decreasing clot lysis . Intravenous proton pump inhibitors have traditionally been used after endoscopic hemostasis

2010 theNNT

132. High-dose vs non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: a systematic review and meta-analysis of randomized controlled trials (Full text)

High-dose vs non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: a systematic review and meta-analysis of randomized controlled trials High-dose vs non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: a systematic review and meta-analysis of randomized controlled trials High-dose vs non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer (...) : a systematic review and meta-analysis of randomized controlled trials Wang CH, Ma MH, Chou HC, Yen ZS, Yang CW, Fang CC, Chen SC CRD summary This generally well-conducted review concluded that high-dose proton pump inhibitors did not reduce re-bleeding, surgical intervention or mortality after endoscopic treatment in patients with a bleeding peptic ulcer, compared with non-high-dose proton pump inhibitors. This conclusion is likely to be reliable. Authors' objectives To determine whether high-dose proton

2010 DARE. PubMed

133. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis

Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

134. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel

Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

135. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia

Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

136. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease (Full text)

Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease The proportion of patients who respond to proton pump inhibitor (PPI) therapy is about 20% lower in those with non-erosive reflux disease (NERD) than in those with erosive oesophagitis.To assess efficacy and safety of dexlansoprazole MR, a PPI using Dual Delayed Release technology, in NERD patients.In this 4-week, double-blind, placebo

2009 EvidenceUpdates PubMed

137. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis (PubMed)

The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis Heartburn and acid reflux are common medical disorders in pregnancy and can result in serious discomfort and complications. Furthermore, some pregnant women also experience more severe gastrointestinal conditions, such as Helicobacter pylori infections, peptic ulcers, and Zollinger-Ellison syndrome. To allow the use of proton pump inhibitors (PPIs) in pregnancy, the fetal safety of this drug class must be established

2009 EvidenceUpdates

138. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel (Full text)

A population-based study of the drug interaction between proton pump inhibitors and clopidogrel Most proton pump inhibitors inhibit the bioactivation of clopidogrel to its active metabolite. The clinical significance of this drug interaction is unknown.We conducted a population-based nested case-control study among patients aged 66 years or older who commenced clopidogrel between Apr. 1, 2002, and Dec. 31, 2007, following hospital discharge after treatment of acute myocardial infarction (...) . The cases in our study were those readmitted with acute myocardial infarction within 90 days after discharge. We performed a secondary analysis considering events within 1 year. Event-free controls (at a ratio of 3:1) were matched to cases on age, percutaneous coronary intervention and a validated risk score. We categorized exposure to proton pump inhibitors before the index date as current (within 30 days), previous (31-90 days) or remote (91-180 days).Among 13 636 patients prescribed clopidogrel

2009 EvidenceUpdates PubMed

139. Proton Pump Inhibitor Association with Increased Risk of Clostridium difficile Associated Diarrhea

Proton Pump Inhibitor Association with Increased Risk of Clostridium difficile Associated Diarrhea "Proton Pump Inhibitor Association with Increased Risk of Clostridium d" by Kitty Earley < > > > > > Title Author Date of Graduation 8-15-2009 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Annjanette Sommers MS, PA-C Second Advisor Rob Rosenow PharmD, OD Rights . Abstract Background: Proton Pump Inhibitor use is increasing in the hospital (...) has been proposed: Proton Pump Inhibitors (PPI). Hypothesis: Hypochlorhydria from PPI is a risk factor for developing CDAD. Study Design: Systematic review of available medical literature and reviews. Methods: An extensive literature search was conducted on Medline-OVID, CINAHL (EBSCOhost), and PubMed using the search terms “proton pump inhibitor and Clostridium difficile”, “Proton Pump Inhibitors”, and “Clostridium difficile”. Relevant references were retrieved and references from the reviewed

2009 Pacific University EBM Capstone Project

140. Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial. (PubMed)

Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial. Substantial physician workload and high costs are associated with the treatment of dyspepsia in primary health care. Despite the availability of consensus statements and guidelines, the most cost-effective empirical strategy for initial management (...) , and proton pump inhibitor (step-up; n=341), or these drugs in the reverse order (step-down; n=323), by use of a computer-generated sequence with blocks of six. Each step lasted 4 weeks and treatment only continued with the next step if symptoms persisted or relapsed within 4 weeks. Primary outcomes were symptom relief and cost-effectiveness of initial management at 6 months. Analysis was by intention to treat (ITT); the ITT population consisted of all patients with data for the primary outcome at 6

2009 Lancet